Hormonal therapy for cancer

Abraham, Jacinta and Staffurth, John Nicholas ORCID: https://orcid.org/0000-0002-7834-3172 2016. Hormonal therapy for cancer. Medicine 44 (1) , pp. 30-33. 10.1016/j.mpmed.2015.10.014

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (253kB) | Preview

Abstract

Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive breast cancer and prostate cancer. Serum levels of oestradiol and testosterone are controlled by the hypothalamic–pituitary–gonadal pathway. Oestradiol is produced in premenopausal women from the ovaries and in postmenopausal women by peripheral conversion of adrenal androgens by aromatase. In premenopausal women with breast cancer and men with prostate cancer, treatment is primarily achieved by castration. In postmenopausal women selective oestrogen receptor modulators (e.g. tamoxifen) or aromatase inhibitors are used. Hormone therapy can be used to reduce the size of the primary cancer prior to radical surgery or radiotherapy or to reduce the risk of recurrence. Hormone therapy is highly effective in patients with locally advanced or metastatic disease, with a high response rate. Most patients eventually relapse with ‘castrate-refractory’ disease, for which increasing numbers of active agents are entering clinical practice.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Uncontrolled Keywords:	Androgen deprivation therapy; anti-androgens; aromatase inhibitors; breast cancer; hormone therapy; prostate cancer; selective oestrogen receptor modulators.
Publisher:	Elsevier
ISSN:	1357-3039
Date of First Compliant Deposit:	2 February 2018
Last Modified:	06 Nov 2023 19:44
URI:	https://orca.cardiff.ac.uk/id/eprint/103187

Citation Data

Cited 9 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item